How do you expect MEIP to pay for a very expensive Phase III trial in elderly AML? There may be some cash in the bank, but not enough for a Phase III in hematology. Dilution at this low share price would be horrible.
What micro-cap biotech do you know that has taken an oncology drug through Phase III pivotal trials successfully on its own? (DNDN was much better financed.)
News 
Market Data 
Discover 
